The study’s results were published on July 26 in the journal Nature Biotechnology.
According to the Parkinson’s Foundation, more than 10 million people globally are living with the disease.
In the US alone, more than one million people have been diagnosed with Parkinson’s – more than the combined total of people diagnosed with multiple sclerosis, muscular dystrophy and ALS.
In the UK, the NHS estimates one in 500 people are affected by the disease, which typically begins to manifest after the age of 50.
As the disease progresses, Parkinson’s causes a decrease in the amount of dopamine in the brain.
Dopamine plays a key role in regulating the body’s movements and its loss accounts for many symptoms, such as tremors and muscle stiffness.
source: express.co.uk